| Autor: |
Hilhorst, Marc, Bemelman, Frederike J, Bruchfeld, Annette, Fernandez-Juarez, Gema M, Floege, Jürgen, Frangou, Eleni, Goumenos, Dimitrios, Kooten, Cees van, Kronbichler, Andreas, Stevens, Kate I, Turkmen, Kultigin, Wiersinga, W Joost, Anders, Hans-Joachim |
| Předmět: |
|
| Zdroj: |
Nephrology Dialysis Transplantation; Aug2023, Vol. 38 Issue 8, p1807-1816, 10p |
| Abstrakt: |
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic led to rapid vaccine development and large global vaccination schemes. However, patients with immune-mediated kidney disease, chronic kidney diseases and kidney transplant recipients show high non-response rates to vaccination despite more than three vaccinations and, consequently, reduced viral clearance capacity when infected while receiving certain immunosuppressants, carrying an elevated risk for coronavirus disease 2019 (COVID-19)-related morbidity and mortality. SARS-CoV-2 evolution has been characterized by the emergence of novel variants and spike mutations contributing to waning efficacy of neutralizing antibodies. To this end, the therapeutic field expands from vaccination towards a combined approach of immunization, pre-exposure prophylaxis and early post-exposure treatment using direct-acting antivirals and neutralizing monoclonal antibodies to treat early in the disease course and avoid hospitalization. This expert opinion paper from the Immunonephrology Working Group of the European Renal Association (ERA-IWG) summarizes available prophylactic and/or early treatment options (i.e. neutralizing monoclonal antibodies and direct-acting antivirals) of SARS-CoV-2-infected patients with immune-mediated kidney disease, chronic kidney disease and kidney transplant recipients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
